Literature DB >> 1001047

Paradoxic bronchospasm after inhalation of isoptroterenol.

J Trautlein, J Allegra, J Field, M Gillin.   

Abstract

Paradoxic bronchospasm induced by adrenergic aerosols, especially isoproterenol, is a well-known clinical entity. It normally occurs in patients who abuse the use of isoproterenol, but has also been reported in a small group of other patients. This study attempted to identify patients who exhibit paradoxic bronchospasm after administration of aerosolized isoproterenol. Forty-one stable, ambulant asthmatics, whose FEV 1.0 was less than 70 percent of predicted normal were studied. None of the asthmatics had taken isoproterenol for one year prior to evaluation. Baseline pulmonary function tests (FVC,FEV 1.09 MMEFR), blood pressure and ECG rhythm strips were recorded, and repeated at 15, 30, 60 and 120 min after administration of isoproterenol. Twenty-nine of the asthmatic patients had the expected normal response ( delta FEV 1.09 15 min: + 579; 30 min: + 464; 60 min: + 372; 120 min: + 307 ml: + 44, + 36, + 23 and + 24 percent) (delta MMEFR, 15 min: + 37; 60 min: + 29; 120 min: + 18L/Min: + 75, + 69, + 47 and + 37 percent). Twelve asthmatic patients (29 percent) had paradoxic bronchospasm (delta FEV 1.09 15 min: - 38; 30 min: - 60; 60 min: - 175; 120 min: - 27 ml; -1, -4, - 10 and - 4 percent) (delta MMEFR - 15 min: - .5; 30 min: - 3; 60 min: - 9; 120 min: - 2L/min; + 4, - 3, - 6 and - 5 percent, P less than 0.001).

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1001047     DOI: 10.1378/chest.70.6.711

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  7 in total

Review 1.  Anomalous effects of albuterol and other sympathomimetics in the guinea pig.

Authors:  J Morley
Journal:  Clin Rev Allergy Immunol       Date:  1996       Impact factor: 8.667

2.  Differential responses of asthmatic airways to enantiomers of albuterol. Implications for clinical treatment of asthma.

Authors:  M Perrin-Fayolle; P S Blum; J Morley; M Grosclaude; M T Chambe
Journal:  Clin Rev Allergy Immunol       Date:  1996       Impact factor: 8.667

3.  Adverse reactions to the non-drug constituents of nebuliser solutions.

Authors:  R Beasley; P Rafferty; S T Holgate
Journal:  Br J Clin Pharmacol       Date:  1988-03       Impact factor: 4.335

4.  Comparison of terbutaline and placebo from a pressurised metered dose inhaler and a dry powder inhaler in a subgroup of patients with asthma.

Authors:  O Selroos; A B Löfroos; A Pietinalho; H Riska
Journal:  Thorax       Date:  1994-12       Impact factor: 9.139

5.  Increased airway reactivity in the guinea-pig follows exposure to intravenous isoprenaline.

Authors:  S Sanjar; A Kristersson; L Mazzoni; J Morley; E Schaeublin
Journal:  J Physiol       Date:  1990-06       Impact factor: 5.182

6.  Inhaled sodium metabisulphite induced bronchoconstriction: inhibition by nedocromil sodium and sodium cromoglycate.

Authors:  C M Dixon; P W Ind
Journal:  Br J Clin Pharmacol       Date:  1990-09       Impact factor: 4.335

Review 7.  The beta 2-agonist controversy. Observations, explanations and relationship to asthma epidemiology.

Authors:  M R Sears; D R Taylor
Journal:  Drug Saf       Date:  1994-10       Impact factor: 5.606

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.